Motif (NASDAQ:MTFB) has received an average rating of “Hold” from the six analysts that are currently covering the firm, Marketbeat reports. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $21.33.
Several brokerages recently issued reports on MTFB. Gabelli restated a “hold” rating on shares of Motif in a research report on Thursday, March 29th. Seaport Global Securities restated a “buy” rating on shares of Motif in a research report on Friday, December 22nd. ValuEngine upgraded shares of Motif from a “strong sell” rating to a “sell” rating in a research report on Friday, February 2nd. Finally, WBB Securities began coverage on shares of Motif in a research report on Friday, December 29th. They set a “sell” rating and a $7.00 target price for the company.
Shares of MTFB traded down $0.04 during mid-day trading on Tuesday, hitting $10.25. 4,430 shares of the company traded hands, compared to its average volume of 1,548. The stock has a market capitalization of $2,010.96, a price-to-earnings ratio of -29.28 and a beta of 0.19. Motif has a 1 year low of $6.75 and a 1 year high of $13.75.
Motif Company Profile
Motif Bio plc, a clinical stage biopharmaceutical company, develops and commercializes pharmaceutical formulations in the United States. The company develops novel antibiotics for the treatment of serious and life-threatening infections caused by multi-drug resistant bacteria. Its lead product candidate is Iclaprim, a novel antibiotic that is in Phase III clinical trials to treat bacterial infections, such as acute bacterial skin and skin structure infections, and hospital acquired bacterial pneumonia caused by methicillin-resistant staphylococcus aureus.
Receive News & Ratings for Motif Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Motif and related companies with MarketBeat.com's FREE daily email newsletter.